Humacyte (HUMA) Invested Capital (2020 - 2026)

Humacyte (HUMA) has 7 years of Invested Capital data on file, last reported at $47.5 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $47.5 million, down 53.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.5 million (down 53.62% YoY), and the FY2025 annual result was $38.6 million, up 173.2% from the prior year.
• Invested Capital climbed to $47.5 million in Q1 2026 per HUMA's latest filing, from $38.6 million in the prior quarter.
• Over five years, Invested Capital peaked at $172.3 million in Q2 2022 and troughed at -$52.7 million in Q4 2024.
• A 5-year average of $72.1 million and a median of $74.3 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital sank 262.33% in 2024, then surged 1661.66% in 2025.
• A 5-year view of Invested Capital shows it stood at $138.0 million in 2022, then plunged by 76.49% to $32.4 million in 2023, then slumped by 262.33% to -$52.7 million in 2024, then soared by 173.2% to $38.6 million in 2025, then grew by 23.19% to $47.5 million in 2026.
• Business Quant data shows HUMA's Invested Capital at $47.5 million in Q1 2026, $38.6 million in Q4 2025, and $25.0 million in Q3 2025.